

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

NCI-H69

RRID:CVCL_1579

Type: Cell Line

Proper Citation

RRID:CVCL_1579

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1579

Proper Citation: RRID:CVCL_1579

Description: Cell line NCI-H69 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung small cell carcinoma

Defining Citation: [PMID:1662924](#), [PMID:1845952](#), [PMID:1847845](#), [PMID:2388294](#), [PMID:2473086](#), [PMID:2574988](#), [PMID:2594029](#), [PMID:2985257](#), [PMID:2985258](#), [PMID:2986243](#), [PMID:3034934](#), [PMID:3335022](#), [PMID:6108156](#), [PMID:6148444](#), [PMID:6270685](#), [PMID:6272398](#), [PMID:6713399](#), [PMID:7736387](#), [PMID:7903701](#), [PMID:8263009](#), [PMID:8626706](#), [PMID:8712684](#), [PMID:8784480](#), [PMID:8806092](#), [PMID:8806103](#), [PMID:9212023](#), [PMID:9413215](#), [PMID:9559344](#), [PMID:9744504](#), [PMID:9815546](#), [PMID:10037197](#), [PMID:10358721](#), [PMID:10536175](#), [PMID:11005564](#), [PMID:11030152](#), [PMID:11414198](#), [PMID:12569360](#), [PMID:17426248](#), [PMID:19394761](#), [PMID:19446745](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:20615970](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:23716474](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28766886](#), [PMID:30038707](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:32351780](#), [PMID:32586373](#), [PMID:34439128](#), [PMID:35839778](#), [PMID:39154123](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H69

Synonyms: NCI-H-69, NCI H69, H69, H-69, NCIH69, NCI-HUT-69, H69/P, NCI-H69C, H69C, H69c

Cross References: BTO:BTO_0003022, CLO:CLO_0003609, CLO:CLO_0008105, EFO:EFO_0002300, CLDB:cl1552, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-119, BioSample:SAMN03473085, BioSample:SAMN10988132, cancercellines:CVCL_1579, CCRID:1101HUM-PUMC000358, Cell_Model_Passport:SIDM01121, ChEMBL-Cells:ChEMBL3307712, ChEMBL-Targets:ChEMBL614805, CLS:300185, Cosmic:688027, Cosmic:713879, Cosmic:755459, Cosmic:801610, Cosmic:808518, Cosmic:844545, Cosmic:844817, Cosmic:876167, Cosmic:877351, Cosmic:918010, Cosmic:929160, Cosmic:1006522, Cosmic:1021849, Cosmic:1152461, Cosmic:1175859, Cosmic:1212189, Cosmic:1219096, Cosmic:1239934, Cosmic:1434964, Cosmic:1571755, Cosmic:1609516, Cosmic:1995588, Cosmic:1998272, Cosmic:2125215, Cosmic:2239080, Cosmic:2648017, Cosmic:2668341, Cosmic-CLP:688027, DepMap:ACH-000358, ECACC:91091802, EGA:EGAS00001000978, GDSC:688027, GEO:GSM169443, GEO:GSM380498, GEO:GSM536334, GEO:GSM784197, GEO:GSM794269, GEO:GSM827305, GEO:GSM844659, GEO:GSM845550, GEO:GSM887442, GEO:GSM888522, GEO:GSM1670258, GEO:GSM1887950, GEO:GSM1887978, IARC_TP53:328, IGRhCellID:NCIH69, IZSLER:BS TCL 172, KCLB:30119, LiGeA:CCLE_927, LINCS_LDP:LCL-1859, NCI-DTP:NCI-H69, PharmacDB:NCIH69_1129_2019, PRIDE:PXD011896, PRIDE:PXD015270, PRIDE:PXD030304, Progenetix:CVCL_1579, PubChem_Cell_line:CVCL_1579, Wikidata:Q38568854

ID: CVCL_1579

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260913T004957+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H69.

No alerts have been found for NCI-H69.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 168 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pan K, et al. (2026) Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. Biochemical

pharmacology, 243(Pt 2), 117562.

Gu JJ, et al. (2026) ABL kinase inactivation induces transcription-replication conflicts and impairs replication fork progression in metastatic small cell lung cancer. *Cell reports*, 45(7), 117699.

Campisi M, et al. (2026) Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer. *Cancer cell*, 44(4), 858.

Chen C, et al. (2026) Targeting STAT3 by SH-4-54 suppresses the occurrence and inactivates oxidative phosphorylation in small-cell lung cancer via the SRC signaling. *Naunyn-Schmiedeberg's archives of pharmacology*, 399(7), 9551.

Balke-Want H, et al. (2026) c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors. *Cell reports. Medicine*, 7(1), 102549.

Ahmad T, et al. (2026) KDM7B-mediated demethylation of RNF113A regulates small cell lung cancer sensitivity to alkylation damage. *bioRxiv : the preprint server for biology*.

Zou X, et al. (2026) Self-assembled chamber-like cardiac organoids for modeling cardiac chamber formation and cardiotoxicity assessment. *Nature communications*, 17(1).

Dhungel N, et al. (2026) Direct interaction between cancer cells and fibroblasts promotes early chemoresistance to standard-of-care drug therapy in small cell lung cancer (SCLC). *bioRxiv : the preprint server for biology*.

Wang W, et al. (2025) Engineering affinity-matured variants of an anti-polysialic acid monoclonal antibody with superior cytotoxicity-mediating potency. *Cell chemical biology*, 32(8), 1042.

Yu J, et al. (2025) In Vitro Anticancer Activity of Phytol on Human Non-Small Cell Lung Cancer A549 Cells. *Integrative cancer therapies*, 24, 15347354251344592.

I??a??ez A, et al. (2025) The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer. *International journal of molecular sciences*, 26(3).

Chakraborty S, et al. (2025) Protocol to co-culture SCLC cells with human CD8+ T cells to measure tumor cell killing and T cell activation. *STAR protocols*, 6(2), 103767.

Kweon TH, et al. (2024) O-GlcNAcylation of RBM14 contributes to elevated cellular O-GlcNAc through regulation of OGA protein stability. *Cell reports*, 43(5), 114163.

Lakhani NJ, et al. (2024) First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(3), 506.

Chakraborty S, et al. (2024) Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. *Cell reports. Medicine*, 5(12), 101852.

Wang Z, et al. (2024) Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators. *Cancer cell*, 42(6), 1106.

Kinoshita S, et al. (2024) Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer. *Cancer research communications*, 4(3), 723.

Ng J, et al. (2024) Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, OF1.

Zhu Q, et al. (2024) Cisplatin resistance-related transcriptome and methylome integration identifies PCDHB4 as a novel prognostic biomarker in small cell lung cancer. *iScience*, 27(8), 110413.

Liu Q, et al. (2024) Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. *Cell*, 187(1), 184.